Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Prostate Cancer Clinical Trial

Official title:

An Exploratory proof-of Mechanism Study to Assess the Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells and Additional Immune Subsets in Prostate Cancer Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03274778
• Other study ID #: IOSI-IOR-001
• Status: Withdrawn
• Phase: N/A
• Start date: September 1, 2017
• Est. completion date: March 24, 2020

Study information

• Verified date: March 2020
• Source: Oncology Institute of Southern Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ruxolitinib will be dispensed to patients candidate to prostatectomy immediately after histological diagnosis of prostate adenocarcinoma. The treatment will be given for 28 days followed by a prostatectomy thereafter.

Tumor material and blood samples will be analysed before, during and after the treatment with Ruxolitinib.

Description:

Patients with suspected localized prostate cancer will undergo biopsies spotting different prostate sites, as per standard clinical practice. Patients with histologically confirmed prostate adenocarcinoma and candidate for prostatectomy, after signing the Informed Consent Form, will receive Ruxolitinib for 4 weeks (the time normally elapsing between histological diagnosis and surgery) and will thereafter undergo prostatectomy.

Remaining biological material from the diagnosis and the prostatectomy will be sent to the Molecular Oncology Laboratory for molecular analysis.

In addition, blood samples will be drawn before, during Ruxolitinib treatment (Week 2), at the end of treatment (Week 4), and after prostatectomy (Week 5), to assess the frequency and subtype of immune subsets and the circulating levels of cytokines and secreted.

Patients will be monitored for occurrence of adverse events/surgical complications during treatment and up to 4 weeks after the intervention.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 24, 2020
• Est. primary completion date: March 24, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18-70 years

• Histological diagnosis of prostate adenocarcinoma

• Stage =T2b for which surgery is indicated

• No distant metastasis (M0)

• NLR =3 in the blood or NLR =3 in the tumor biopsies or a percentage of MDSCs = 30% in the tumour biopsies

• PS (ECOG scale) 0-1

• Adequate hepatic function: ALT and ASAT = 2.5 x ULN, Bilirubin = 1.5 ULN (exception if Gilbert's syndrome = 2.5 x ULN)

• Adequate renal function: calculated creatinine clearance = 50 ml/min according to the formula of Cockcroft-Gault

• Hemoglobin = 10 g/dl, leukocyte count = 4.0 x 103/µl, platelet count = 200 x 103/µl

• Informed Consent as documented by the patient's signature

Exclusion Criteria:

• No history of coagulation disorders and normal INR

• Significant cardiovascular disorders in the last 12 months

• Other clinically significant concomitant disease states which in the opinion of the Investigator may represent contraindications to study participation

• Known or suspected non-compliance

• Participation in another study with investigational drug within the 30 days preceding and during the present study

• Ongoing treatment with strong CYP3A4 inhibitors or dual CYP2C9 and CYP3A4 inhibitors

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Ruxolitinib 20 MG
tablets

Locations

Country	Name	City	State
Switzerland	Istituto Oncologico della Svizzera Italiana (IOSI)	Bellinzona

Sponsors (1)

Lead Sponsor	Collaborator
Oncology Institute of Southern Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor immune response	Tumor immune response modification induced by Ruxolitinib	9 wks
Secondary	pSTAT3	Decrease of pSTAT3	5 wks
Secondary	Cytokines	Reduction of cytokines associated to myeloid cells recruitment and tumor-promoting factors (e.g. IL8, IL6, TGF)	6 wks
Secondary	KI-67	Reduction by 50% of KI-67	9 wks
Secondary	biomarkers	Increase of senescence and apoptosis markers (p16, p21, Beta-galactosidase, Caspase-3, Caspase-8)	5 wks